NASDAQ:IPA ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis $0.46 -0.02 (-4.19%) (As of 04:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About ImmunoPrecise Antibodies Stock (NASDAQ:IPA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IPA alerts:Sign Up Key Stats Today's Range$0.43▼$0.4950-Day Range$0.39▼$0.6852-Week Range$0.35▼$2.60Volume378,122 shsAverage Volume352,349 shsMarket Capitalization$13.26 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Read More… Elon Musk has put himself in their crosshairs (Ad)Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. ImmunoPrecise Antibodies Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks54th Percentile Overall ScoreIPA MarketRank™: ImmunoPrecise Antibodies scored higher than 54% of companies evaluated by MarketBeat, and ranked 621st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunoPrecise Antibodies has only been the subject of 1 research reports in the past 90 days.Read more about ImmunoPrecise Antibodies' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.30) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoPrecise Antibodies is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoPrecise Antibodies is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoPrecise Antibodies has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ImmunoPrecise Antibodies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.05% of the float of ImmunoPrecise Antibodies has been sold short.Short Interest Ratio / Days to CoverImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoPrecise Antibodies has recently increased by 355.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunoPrecise Antibodies does not currently pay a dividend.Dividend GrowthImmunoPrecise Antibodies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.05% of the float of ImmunoPrecise Antibodies has been sold short.Short Interest Ratio / Days to CoverImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoPrecise Antibodies has recently increased by 355.92%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.43 News SentimentImmunoPrecise Antibodies has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ImmunoPrecise Antibodies this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added ImmunoPrecise Antibodies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.Percentage Held by InstitutionsOnly 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions.Read more about ImmunoPrecise Antibodies' insider trading history. Receive IPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address IPA Stock News HeadlinesImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics InnovationNovember 4, 2024 | businesswire.comImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI TechnologyOctober 28, 2024 | businesswire.comElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.November 14, 2024 | Porter & Company (Ad)Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts DistrictOctober 16, 2024 | businesswire.comImmunoPrecise Antibodies earnings preview: what Wall Street is expectingSeptember 15, 2024 | markets.businessinsider.comImmunoprecise Antibodies Ltd MediaAugust 27, 2024 | lse.co.ukImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New YorkAugust 26, 2024 | businesswire.comImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid RequirementsAugust 23, 2024 | businesswire.comSee More Headlines IPA Stock Analysis - Frequently Asked Questions How have IPA shares performed this year? ImmunoPrecise Antibodies' stock was trading at $1.71 at the beginning of the year. Since then, IPA shares have decreased by 73.2% and is now trading at $0.4582. View the best growth stocks for 2024 here. How were ImmunoPrecise Antibodies' earnings last quarter? ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) issued its quarterly earnings data on Monday, September, 16th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The firm had revenue of $3.85 million for the quarter, compared to the consensus estimate of $4.96 million. ImmunoPrecise Antibodies had a negative trailing twelve-month return on equity of 65.37% and a negative net margin of 114.67%. How do I buy shares of ImmunoPrecise Antibodies? Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ImmunoPrecise Antibodies own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), General Electric (GE) and ServiceNow (NOW). Company Calendar Last Earnings9/16/2024Today11/14/2024Next Earnings (Estimated)12/12/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IPA CUSIPN/A CIK1715925 Webwww.immunoprecise.com Phone250-483-0308FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,150.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,130,000.00 Net Margins-114.67% Pretax Margin-123.51% Return on Equity-65.37% Return on Assets-40.29% Debt Debt-to-Equity Ratio0.36 Current Ratio0.99 Quick Ratio0.82 Sales & Book Value Annual Sales$18.16 million Price / Sales0.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book0.52Miscellaneous Outstanding Shares28,830,000Free Float26,863,000Market Cap$13.84 million OptionableNot Optionable Beta0.13 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:IPA) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.